

PHARMANUTRA OBTAINS A PATENT FOR CETILAR® RM
Intellectual property rights acknowledged to the patent, expiring in 2035, which
provides official confirmation of the innovative nature and unique properties of
Cetilar

Pisa, 6 April 2018 – A fundamental new strategic corporate asset joins those already held by [PharmaNutra](#) (Aim Italia - Ticker PHN), a nutraceutical company that leads the market in the oral iron products sector. On 5 February 2018, the company was granted a patent for Cetilar® RM (number 102015000044822) by the Italian Patents Office. Applied for in 2015, the patent will be valid for 20 years, expiring in 2035.

Validity is determined by the date on which the patent application is filed, after which no other party may file an application or sell the product, so the patent is considered valid for the period of more than two years before it was officially granted. However, it becomes the intellectual property of the applicant only when the patent is granted, and this right is guaranteed for 20 years. Therefore, from this year, the patent for Cetilar® RM officially becomes a strategic corporate asset of PharmaNutra.

Cetilar® is a unique product, the result of the innovation and scientific research conducted by PharmaNutra Group, launched on the market in October 2016. This cream, made with cetylated esters (7.5% CFA), is aimed primarily at sportsmen and women seeking to avoid having to give up the activity they love due to muscle discomfort or joint problems. Also available in a Patch version, Cetilar® aids movement in individuals suffering from joint ailments caused by osteoarthritis, thus helping to ease musculoskeletal pain and aiding recovery of mobility and rehabilitation following inflammatory phenomena or sports injuries to joints and/or muscles.

The confirmation of the granting of the patent is the crowning achievement of years of study and scientific research conducted by PharmaNutra Group, one of the finest in the Italian nutraceutical sector. These successful research efforts have also allowed us to export our products to foreign markets.

This patent provides official confirmation of the innovative nature and unique properties of Cetilar®, with which PharmaNutra is present in a number of sports, starting with football – as the main sponsor of Parma Calcio – and also including running (with the organisation and sponsorship of numerous events), sailing, thanks to the famous 151 Miglia race, and motorsport, with the Cetilar Villorba Corse team.

PharmaNutra S.p.A.

Founded in Pisa in 2003 and headed by the Chairman Andrea Lacorte and the Vice Chairman Roberto Lacorte, the aim of PharmaNutra is to develop innovative nutraceutical products and medical devices. An outstanding name in the Italian pharmaceutical sector, the company is present in 38 countries worldwide, and directly employs some 50 people (nine of them researchers). The company has its own network of around 150 pharmaceutical representatives, and collaborates, amongst others, with the Universities of Pisa, Milan, Brescia, Modena, Verona, Barcelona and Brisbane. PharmaNutra is currently European market leader in iron-based dietary supplements, with the patented product SiderAL, which in Italy holds a value market share of 50% of the OTC oral iron market. 2017 saw the market debut of Cetilar, a formulation fully patented and produced by PharmaNutra, which confirms the excellent quality of the scientific research carried out by the Tuscan company. <http://www.PharmaNutra.it>

For Information:**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office**Spriano Communication&Partners**

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com